Back to Search
Start Over
Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors
- Source :
- Current Medical Research and Opinion. 36:1363-1373
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Breast cancer is the most frequent cancer amongst women worldwide including in Asia where the incidence rate is rapidly increasing. Even with treatment, around 30% of patients with early breast cancer progress to metastatic disease, with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer the most common phenotype. First-line endocrine therapy targeting the estrogen receptor signaling pathway provides a median progression-free survival or time to progression of 6-15 months in HR + HER2- metastatic breast cancer. Recently, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, combined with endocrine therapy, have achieved more than two years median progression-free survival in HR + HER2- metastatic breast cancer. However, the characteristics of the Asian breast cancer population differ from those of Western populations and need to be considered when selecting a suitable treatment. Breast cancer is diagnosed at a younger age in Asian populations and late stage at presentation is generally more common in low-/middle-income countries than high-income countries. Consequently, the proportion of premenopausal women with metastatic breast cancer is higher in Asian compared with Western populations. While CDK4/6 inhibitors have been approved in the USA (FDA) since 2015, experience with them in Asia is more limited. We review the experience with the CDK4/6 inhibitor palbociclib in Asian patients with HR + HER2- metastatic breast cancer and provide guidance on the use of palbociclib in these patients.
- Subjects :
- Adult
Oncology
medicine.medical_specialty
Pyridines
Receptor, ErbB-2
Breast Neoplasms
030204 cardiovascular system & hematology
Palbociclib
Piperazines
03 medical and health sciences
0302 clinical medicine
Breast cancer
Asia pacific
Internal medicine
medicine
Humans
030212 general & internal medicine
Neoplasm Metastasis
skin and connective tissue diseases
Protein Kinase Inhibitors
business.industry
Perspective (graphical)
Endocrine therapy
Cyclin-Dependent Kinase 4
food and beverages
Cancer
Cyclin-Dependent Kinase 6
General Medicine
Middle Aged
medicine.disease
Metastatic breast cancer
Progression-Free Survival
Receptors, Estrogen
Female
business
Subjects
Details
- ISSN :
- 14734877 and 03007995
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Current Medical Research and Opinion
- Accession number :
- edsair.doi.dedup.....2642d890177f277b9749f679550d3a68